Ovarian Seromucinous Carcinoma
NCI Definition: A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous epithelium. 
Ovarian seromucinous carcinomas most frequently harbor alterations in TP53, PIK3CA, KRAS, and KMT2D .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and KRAS Mutation are the most common alterations in ovarian seromucinous carcinoma .
There is 1 clinical trial for ovarian seromucinous carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains ovarian seromucinous carcinoma as an inclusion criterion, 1 is phase 1 (1 open).
Thorium th 227 anetumab is the most common intervention in ovarian seromucinous carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.